Pediatric Pharmacy Specialty Certification (BCPPS®)
Target Population: Pharmacists who have met the eligibility criteria and who design, implement, monitor, and modify pharmacotherapeutic treatments for pediatric patients.
Program Purpose: To validate that the pharmacist has the advanced knowledge, skills, and experience necessary to optimize safety and outcomes for the pediatric patient population.
Currently there are more than 1,970 BPS Board-Certified Pediatric Pharmacy Specialists.
Pediatric Pharmacy Specialty Council Members
The purpose of the BPS Specialty Councils is to develop standards and eligibility requirements for board certification, develop examinations and passing standards for certification, and review and approve professional development programs for recertification of board-certified pharmacists. Specialty council members are at the heart of the peer-reviewed and peer-developed nature of BPS Board Certification.
Bogenschutz is a Pediatric Clinical Pharmacist and PGY2 Pediatric Pharmacy Residency program director at UW Health – American Family Children’s Hospital in Madison, WI. Her primary clinical practice areas include the pediatric and neonatal intensive care units. She is a member of the Pediatric Antimicrobial Stewardship Team and provides support and coordination for pediatric practice standardization, advancement, and quality improvement initiatives. She serves as a preceptor for pharmacy students, PGY1 Pharmacy Practice, PGY2 Critical Care, and PGY2 Emergency Medicine Residents on pediatric/neonatal intensive care rotations. Bogenschutz received her Bachelor of Science in Biology and Doctor of Pharmacy degrees from the University of Wisconsin-Madison, completed a PGY1 pediatric pharmacy practice residency at Lucile Packard Children’s Hospital at Stanford, and is Board Certified in Pharmacotherapy and Pediatrics.
Cassandra is a Clinical Pharmacy Informaticist at Akron Children’s Hospital in Akron, OH. She received her PharmD from LECOM Bradenton, completed a PGY1 at Sarasota Memorial Hospital in Sarasota, Fl and a PGY2 at Children’s National Medical Center in Washington, DC and is Board Certified in both Pediatrics, and Critical Care Pharmacy. She previously practiced as a PICU clinical pharmacy specialist at Akron Children’s Hospital for almost 10 years.
Autry is a Pediatric Clinical Pharmacist at Kentucky Children’s Hospital at UK HealthCare in Lexington, Kentucky, Adjunct Associate Professor at the University of Kentucky College of Pharmacy and Association Professor at the University of Kentucky College of Medicine, Department of Pediatrics. She provides pharmacy support to the pediatric pulmonary, allergy and immunology service and serves as the residency program director for the PGY2 Pediatric pharmacy residency program. Autry preceptors pharmacy residents and students in her primary patient care area. Autry received her PharmD from the University of North Carolina at Chapel Hill Eshelman School of Pharmacy, completed a PGY1 at ECU Health (formerly Vidant Health), and PGY2 pediatric pharmacy residency at the University of Kentucky, and is Board Certified in Pediatric Pharmacy.
Dr. Cohen is a consultant/advisor, educator, mentor, and researcher with over 40 years of experience. He has been a Board-Certified Psychiatric Pharmacist since 1996. He is Distinguished Professor of Pharmacotherapy at the University of North Texas and Emeritus Professor of Pharmacotherapy at Washington State University College of Pharmacy. He has also had faculty appointments at the University of Cincinnati, University of Oklahoma, University of Maryland, and University of California, San Francisco. He currently continues to serve as Adjunct Professor in the College of Pharmacy, Texas College of Osteopathic Medicine at the UNT Health Science Center. He has been elected Fellow of the American College of Clinical Pharmacy, American Society of Health-System Pharmacists, American College of Clinical Pharmacology and Fellow and Distinguished Practitioner of the National Academies of Practice – Pharmacy Academy. He has been elected to serve in leadership positions in many professional societies including ACCPharmacy, ACCPharmacology, American Pharmacists Association, and the American Association of Psychiatric Pharmacists. He earned his Doctor of Pharmacy degree at the University of Southern California School of Pharmacy and completed a postdoctoral residency in psychiatric pharmacy at the LA County/USC Medical Center. His scholarly interests include pharmacokinetics and pharmacodynamics of psychotropic medications, clinical psychopharmacology, pharmacoeconomics and health outcomes, pharmacoepidemiology, and access and affordability of healthcare.
Amy is a Pediatric Clinical Pharmacist currently practicing at MHealth Fairview – University of Minnesota Masonic Children’s Hospital. She completed a PGY1 residency at Sanford Health, as well as a PGY2 Pediatric Residency at Fairview – University of Minnesota Amplatz Children’s Hospital. Since then, she has served as a Pediatric ICU and Emergency Medicine specialist at Mayo Clinic (Rochester) and University of Wisconsin American Family Children’s Hospital. Her areas of interest include emergency medicine, neurology, and complex pediatric patients. She actively participates in medication use quality improvement initiatives, and precepts PGY1 and PGY2 residents in emergency medicine and PICU rotations. She is Board Certified in Pediatrics.
Brent Hall is currently a Pharmacy Specialist in Pediatrics at the UC Davis Medical Center and Associate Clinical Professor at the UCSF College of Pharmacy. He graduated from Purdue University in 1999 and then subsequently matched with a residency position at Northwestern Memorial Hospital in Chicago, Illinois. After completion of his residency, Brent accepted a position at University Medical Center in Tucson, Arizona. Brent first served as a staff pharmacist in pediatrics before advancing to the position of Clinical Coordinator for Pediatric Pharmacy. In addition, Brent was also very active in the Schools of Pharmacy, Medicine and Nursing providing didactic lectures, precepting and course coordination. In 2014, Brent moved his practice to Sacramento, California to help with the establishment of the PGY 2 Pediatric Pharmacy Residency Program and expansion of clinical services. Ongoing research includes studies evaluating the utility of Gabapentin in Pediatric Cardiothoracic Surgery patients in decreasing the need for opioids, non-inferiority evaluation of 30 mg/kg of Metronidazole for pediatric colorectal surgery prophylaxis, optimal timing of antiXa levels for Enoxaparin monitoring and evaluation of incidence of compassion fatigue in pharmacy residents. Nationally he is actively involved in ASHP, ACCP, PPAG and has given multiple local, state and national presentations on precepting. Brent’s areas of interest include critical care medicine, sedation/delirium management, pain control, anticoagulation, teaching and wellness.
Benjamin Hammer is currently the Director of Clinical Pharmacy at Boston Children’s Hospital in Boston, MA. Benjamin’s first career was in the arts as a musical theatre actor in Atlanta, GA. He took a left turn in 2008 and later graduated from Mercer University in 2013 with his Pharm.D. He went on to complete his PGY1 at The University of Illinois – Chicago in Chicago, Illinois and PGY2 in Pediatrics at The University of Maryland in Baltimore, MD. Benjamin accepted a position at Children’s National Hospital as the inaugural Infectious Diseases Clinical Pharmacy Specialist. Benjamin helped establish the ASP program at CNH in 2016, and he also implemented a pharmacy intervention tracking software program. In 2017, Benjamin became the Residency Program Director at CNH and became the Clinical Pharmacy Manager, more than doubling the size of clinical team in his nearly 5 years in the role. After a brief departure from CNH in 2022, Benjamin returned to take on the role of Ambulatory Clinical Manager overseeing collaborative practice efforts as well as the transitions of care team. Benjamin most recently joined the incredible team at Boston Children’s in June 2025. Publications have included work in both the Infectious Diseases space as well as administrative efforts including managing an IVIG shortage and drug waste in the OR. Nationally he is actively involved in ASHP and PPA and has given multiple local, state and national presentations as well as lectures at local universities. Benjamin’s areas of interest include infectious diseases, leadership, teaching and mentorship.
Dr. Nichols is a Senior Clinical Content Consultant at Wolters Kluwer Health, primarily contributing to the UTD Lexidrug product. She earned her Doctor of Pharmacy degree at Butler University in Indianapolis, IN. She then completed a PGY1 Pharmacy Residency at Indiana University Health and a PGY2 Pediatric Pharmacy Residency at Riley Hospital for Children at IU Health. Prior to transitioning to Wolters Kluwer, Nichols was a tenured Associate Professor of Pharmacy Practice at Butler University and practiced in Pediatric Infectious Diseases and Antimicrobial Stewardship at Riley Hospital for Children and in Antimicrobial Stewardship and research at Franciscan Health Indianapolis.
Pooja Shah is a Clinical Pharmacy Specialist in Neonatal Intensive Care and General Pediatrics at Hackensack University Medical Center and Clinical Associate Professor at Rutgers University, The State University of NJ. She earned her doctor of pharmacy from Rutgers University and completed her PGY 1 Pharmacy Residency and PGY 2 Pediatric Pharmacy Residency at Hackensack University Medical Center and University of Chicago Medicine, respectively. She is actively involved in PPA and ASHP. Her areas of interest include management of neonatal and pediatric infectious diseases, antimicrobial stewardship and pharmacy education.
Mary Subramanian is a pharmacy manager for pediatric operations and clinical services, abdominal transplant, infectious diseases and behavioral health at, Atrium Health Wake Forest Baptist and serves as the PGY2 Pediatric Residency Program Director. Subramanian received her Doctor of Pharmacy degree from the University of Kansas. She completed a PGY1 residency at Wesley Medical Center and a PGY2 pediatric residency at Wake Forest Baptist. Subramanian is Board Certified in Pharmacotherapy and Pediatrics. She is actively engaged in quality improvement initiatives and practice optimization within the health system.
Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, FAMCP is a board-certified ambulatory care and geriatric pharmacist with more than 15 years of experience in managed care pharmacy, pharmacy benefit management (PBM), specialty pharmacy, and health systems. Her professional work focuses on optimizing medication use, advancing evidence-based decision-making, and improving patient outcomes through benefit design and clinical program development.
Dr. Taddei-Allen previously served as Vice President of Clinical Programs and Services at WellDyne, where she led multidisciplinary clinical initiatives addressing chronic disease management, opioid stewardship, specialty pharmacy, and medical–pharmacy integration. Her work incorporated real-world evidence, patient-reported outcomes, and population health strategies to support formulary decision-making and quality improvement.
She currently serves as a Clinical Assistant Professor at the University of Florida College of Pharmacy and as faculty at Lake Erie College of Medicine (LECOM), where she teaches Managed Care, Pharmacy Benefit Design and Management, and Specialty Pharmacy. Dr. Taddei-Allen is a Fellow of the Academy of Managed Care Pharmacy, Immediate Past-President of Florida AMCP, a member of the AMCP National Professional Practice Committee, and Secretary of the AMCP Women’s Integration Network (WIN). She has authored and presented extensively on managed care pharmacy, outcomes research, and patient-centered care, and is committed to advancing pharmacy practice through education, leadership, and board certification.
Susan Villegas, PharmD, BCPPS is a clinical pharmacy leader with over two decades of experience in pediatrics and academia. She is Board Certified in Pediatric Pharmacy. Dr. Villegas is currently the Manager for Clinical Pharmaceutical Services at University Hospital in Newark, NJ and serves as an Adjunct Assistant Clinical Professor of Pharmacy Sciences at Columbia University School of Nursing.
Dr. Villegas earned her Doctor of Pharmacy Degree from West Virginia University and completed a Pharmacy Practice Residency with an emphasis in Pediatrics at Children’s Minnesota – Minneapolis Hospital. Her areas of interest/past practices include general pediatrics, infectious diseases, and medication safety.
Eligibility Requirements
An applicant for board certification in Pediatric Pharmacy must demonstrate all of the eligibility requirements listed below. All practice and education eligibility requirements must be met before submitting the application. Once all of the requirements below are met, an applicant will be deemed eligible to sit for the Pediatric Pharmacy specialty certification examination. If an applicant achieves a passing score on the Pediatric Pharmacy specialty certification examination, they may use the designation Board-Certified Pediatric Pharmacy Specialist, or BCPPS®.
- Refer to the Pediatric Pharmacy Examination Content Outline here for details on eligibility requirements, effective dates, and more.
The rationale for the appropriateness of the requirements for BPS certification programs are based upon the following:
- BPS recognizes individuals who graduate from a recognized school or college of pharmacy within the candidate’s jurisdiction. Those jurisdictions recognize and evaluate programs on the extent to which it accomplishes its stated goals and is consistent with the concept that pharmacy is a unique, personal service profession in the health science field. In the United States, the responsibility for recognizing schools and colleges of pharmacy falls to the Accreditation Council for Pharmacy Education (ACPE).
- The rationale for requiring licensure or registration of pharmacists within their jurisdiction is based upon the fact that for public protection, all pharmacists must be licensed or registered. This is considered a baseline requirement to be a pharmacist specialist. In the United States, BPS recognizes the licensure process administered by the National Association of Boards of Pharmacy (NABP). The National Association of Boards of Pharmacy (NABP) aims to ensure the public’s health and safety through its pharmacist license transfer and pharmacist competence assessment programs. NABP’s member boards of pharmacy are grouped into eight districts that include all 50 United States, the District of Columbia, Guam, Puerto Rico, the Virgin Islands, Bahamas, and all 10 Canadian provinces.
- The experiential component is required to help assure practical application of components of the specialty knowledge being certified. There are multiple pathways to meet the practice experience requirement. The faster eligibility pathways recognize accredited residencies through the American Society of Health System Pharmacists (ASHP). The ASHP residency accreditation program identifies and grants public recognition to practice sites having pharmacy residency training programs that have been evaluated and found to meet the qualifications of one of the ASHP’s residency accreditations standards. Thus, accreditation of a pharmacy residency program provides a means of assurance to residency applicants that a program meets certain basic requirements and is, therefore, an acceptable site for postgraduate training in pharmacy practice in organized health care.
- Passing the BPS pharmacy specialty examination helps assure knowledge consistent with the validated content outline for the BPS specialty.
The appropriateness of the BPS program requirements are consistent with the Council on Credentialing in Pharmacy’s Resource Paper titled: Scope of Contemporary Pharmacy Practice: Roles, Responsibilities, and Functions of Pharmacists and Pharmacy Technicians.
Upcoming Deadlines
Candidate's Guide
The Candidate’s Guide is intended for use by pharmacists who are interested in becoming certified as specialists by BPS in any of the BPS-recognized specialty practice areas. To review critical information for BPS Certification Examinations, visit this page.
Content Outline for BCPPS
Refer to the Pediatric Pharmacy Examination Content Outline here for details on eligibility requirements, effective dates, and more.
The examination content outline is a product of a job analysis, also known as a role delineation study, that includes discussions with a panel of 15-20 subject matter experts who represent the specialty area. These experts determine the competencies required for safe and effective pharmacy practice in the specialty area and engage board-certified pharmacists through a validation survey for their endorsement of the identified competencies. The job analysis process is conducted every 5 years to help ensure that the competencies in the examination content outline reflect current pharmacy practice in the specialty area.
Click here to review the BCPPS® Job Analysis Summary.
Important Resources
Preparing for the BCPPS Examination
Certification is a significant differentiator, and the rigorous exam process requires concentrated study. Successful candidates are well prepared, and a number of available resources can assist pre-qualified applicants.
Suggested preparation for the examination might include:
- The study of journal articles, textbooks or other publications related to the Content Outline.
- Attendance at continuing education programs and courses in specialized pharmacy practice.
- Participation in study groups and examination preparation courses.
- Reviewing the sample examination items provided in order for candidates to familiarize themselves with the various item formats which are presented on the exam. Sample question performance should not be interpreted as an indicator of exam performance.
To maintain its strict, independent standards for certification, BPS does NOT provide review information, preparatory courses, or study guides. However, such materials are available from outside organizations, state or local professional associations and colleges of pharmacy. Potential applicants may contact the professional associations noted below for additional study resources.
The Board of Pharmacy Specialties provides the following program listing for informational purposes. This list is not an exhaustive list of options available for examination preparation. BPS does not endorse or provide preparatory courses for Board Certification Examinations.
Pediatric Pharmacy
- American College of Clinical Pharmacy
(913) 492-3311
American Society of Health-System Pharmacists
(866) 279-0681
https://www.rxcertifications.org/pediatric-pharmacy
- Pediatric Pharmacy Association
(901) 820-4434
https://www.pathlms.com/ppa
BPS partners with Pearson to provide the examination. BPS does not have any other partnerships for the certification or recertification application process. BPS partners with professional development program (PDP) providers to provide continuing pharmacy education (CPE) for recertification and the relationship is noted here. Any organization claiming a relationship with BPS for the application process or providing CPE labeled ‘BPS-approved’ outside of the organizations listed should be reported to BPS immediately.
Certification for Applicants Outside the U.S.
BPS would like to offer some helpful tips to candidates outside of the United States in order to make their application experience easier. To learn more about applying for board certification as a pharmacist outside of the U.S., visit this page.
Apply for ADA Accommodations
BPS complies with the relevant provisions of the Americans with Disabilities Act (ADA). For applicants looking to request special accommodations in their application process, more instructions can be found on this page.
Frequently Asked Questions
After review of the BPS Candidates Guide and specialty certification page, some applicants may still have questions. Visit this page to see frequently asked questions from pharmacists pursuing board certification like you!
Sample Examination Items
Sample Items for BCPPS® Examinations
The sample examination items for BCPPS® examinations are made available by BPS for the purposes of familiarizing certification candidates and other stakeholders with the structure and format of BPS Certification Examinations. This is not meant for use as a self-assessment. Performance on any of these items does not correlate with performance on the actual examination.
The content of these examples is meant to be illustrative of actual examination items, but these items do not appear on the certification examination and are not meant to identify the scope of the examination. For a more comprehensive indication of the scope of the certification examination, please refer to the BCPPS® Exam Content Outline.
Examination items are in multiple-choice format. The great majority of examination items are multiple-choice with a single response from among four options. Some examinations may include a small percentage of items that require selection of multiple (three or four) responses from among a larger set of available (up to eight) options. Examinations items may also be supplemented by an image.
View the examination items down below.
Using the Mosteller equation, what is the estimated body surface area of a 6-year-old patient who is 122 cm tall and weighs 24 kg?
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
A patient with asthma in the emergency department is still in distress after receiving three treatments of albuterol/ipratropium and methylprednisolone 1 mg/kg. Which adjunctive therapy would be most appropriate?
Correct!
Incorrect!
| Na | 150 mEq/L |
| K | 4.1 mEq/L |
| Cl | 100 mEq/L |
| HCO3- | 4 mEq/L |
| BUN | 25 mg/dL |
| SCr | 1.2 mg/dL |
| Glucose | 459 mg/dL |
| Venous pH | 6.9 |
Which treatment should be initiated first to treat this child's underlying illness?
Correct!
Incorrect!
An 8-year-old child reports leg swelling and decreased urine output. Urinalysis is significant for 500 ng/dL protein and positive for nitrite. A renal biopsy shows focal segmental glomerulosclerosis. Which initial treatment is most appropriate for this child?
Correct!
Incorrect!
Which is the most appropriate first-line treatment for functional constipation in a 1-year-old child?
Correct!
Incorrect!
A 16-day-old full-term neonate presents to the emergency department with seizures. Sepsis and meningitis are suspected, and cultures are obtained. Which antibiotic regimen is most appropriate for this neonate?
Correct!
Incorrect!
Which alternative therapy has shown effectiveness in treating irritable bowel syndrome in pediatric patients?
Correct!
Incorrect!
Which category is described as "Error, Death" by the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP)?
Correct!
Incorrect!
Which is an accurate statement regarding permission for patient participation in a study?
Correct!
Incorrect!
A new diagnostic test to be used in children has been developed. The clinical testing reveals the following:
| True positive | 145 |
| False positive | 30 |
| True negative | 50 |
| False negative | 5 |
What is the positive predictive value for this test?
Correct!
Incorrect!
Share the quiz to show your results !
Subscribe to see your results
I got %%score%% of %%total%% right
Loading...
Recertification Requirements for BCPPS®
Pharmacists who earn the designation Board-Certified Pediatric Pharmacy Specialist (BCPPS®) are required to maintain their certification over a seven-year period by completing one of the following recertification pathways:
Option One: Recertification Examination
- For BCPPS® with certification beginning January 1, 2023 or earlier: Achieve a passing score on the recertification examination administered by BPS.
- For BCPPS® with certification beginning January 1, 2024 or later: Achieve a passing score on the recertification examination administered by BPS and self-report up to 20 units of continuing professional development (CPD). Assessed continuing pharmacy education (CPE) from BPS-approved professional development programs can also satisfy this requirement. For more information on CPD, review the FAQ. To maintain an active certification in good standing, a minimum of two units of assessed CPE from BPS-approved professional development programs or self-reported CPD must be reported each year.
OR
Option Two: Professional Development Program
- For BCPPS® with certification beginning January 1, 2023 or earlier: recertification via professional development program requires 100 units of assessed CPE from BPS-approved professional development programs offered by:
- The American Society of Health-System Pharmacists (ASHP) in collaboration with the American College of Clinical Pharmacy (ACCP), and/or
- The Pediatric Pharmacy Association (PPA).
- BCPPS® may participate in recertification from any BPS-approved BCPPS® programs.
- For BCPPS® with certification beginning January 1, 2024 or later: recertification via professional development program requires 100 units. Earn at least 80 units of assessed continuing pharmacy education (CPE) from BPS-approved professional development programs and self-report up to 20 units of continuing professional development (CPD) by the end of the 7 year recertification cycle (assessed CPE can also satisfy this requirement).*
- The American Society of Health-System Pharmacists (ASHP) in collaboration with the American College of Clinical Pharmacy (ACCP), and/or
- The Pediatric Pharmacy Association (PPA).
- * A minimum of 2 units of CPD or BPS-approved, assessed CPE must be earned annually, regardless of recertification pathway.
- BCPPS® may participate in recertification from any of the BPS-approved BCPPS® programs.
Click here to view a simplified comparison infographic to learn more about the differences between the CPE and CPD recertification frameworks.
| Year certified/recertified | New cycle start (begin earning recert units) | Cycle expiration (deadline to meet recert reqs) | Units required (PDP = professional development program) |
| 2019 | 1/1/2020 | 12/31/2026 | 100 units assessed CPE via BPS-approved PDP |
| 2020 | 1/1/2021 | 12/31/2027 | 100 units assessed CPE via BPS-approved PDP |
| 2021 | 1/1/2022 | 12/31/2028 | 100 units assessed CPE via BPS-approved PDP |
| 2022 | 1/1/2023 | 12/31/2029 | 100 units assessed CPE via BPS-approved PDP |
| 2023 | 1/1/2024 | 12/31/2030 | 100 units (80 units assessed CPE via BPS-approved PDP + 20 units CPD) |
| 2024 onward | 1/1/2025 onward | 12/31/2031 onward | 100 units (80 units assessed CPE via BPS-approved PDP + 20 units CPD) |
For full details regarding recertification, please refer to the BPS Recertification Guide.
Board-Certified Pediatric Pharmacy Specialists® are required to pay the BPS Annual Certification Maintenance fee of $125 each year for years one through six and the $400 recertification fee in year seven. Individuals with more than one BPS certification are assessed one BPS Annual Certification Maintenance Fee each year.
Upcoming Deadlines
Candidates are required to recertify every 7 years. Certificants must submit their recertification application no later than the deadline of August 17. BPS encourages candidates to submit their recertification application as early as January 1 of their recertification year.
Candidates who intend to recertify via examination should note the availability of the recertification examination and related application deadlines. Candidates recertifying their BCPPS credential by examination can find more information about examination dates and fees here.
Candidates who intend to recertify via continuing pharmacy education (CPE) MUST submit their recertification application by the deadline date of August 17 even if they have not completed their CPE requirements.
The deadline to complete the required CPE for recertification is December 31 for all specialties. The board-certified pharmacist is responsible for submitting an application that is completely and accurately filled out. Incomplete and/or unpaid applications will not be processed.
Recertification Guide
CPE Providers
BCPPS® with certification beginning January 1, 2023 or earlier: recertification via professional development program requires 100 units of assessed CPE from BPS-approved professional development programs offered by:
- The American Society of Health-System Pharmacists (ASHP) in collaboration with the American College of Clinical Pharmacy (ACCP) and/or
- The Pediatric Pharmacy Association (PPA).
BCPPS® may participate in recertification from any BPS-approved BCPPS® programs.
BCPPS® with certification beginning January 1, 2024 or later: recertification via professional development program requires 100 units. Earn at least 80 units of assessed continuing pharmacy education (CPE) from BPS-approved professional development programs and self-report up to 20 units of continuing professional development (CPD) by the end of the 7 year recertification cycle (assessed CPE can also satisfy this requirement).*
- The American Society of Health-System Pharmacists (ASHP) in collaboration with the American College of Clinical Pharmacy (ACCP) and/or
- The Pediatric Pharmacy Association (PPA).
* A minimum of 2 units of CPD or BPS-approved, assessed CPE must be earned annually, regardless of recertification pathway.
BCPPS® may participate in recertification from any BPS-approved BCPPS® programs.
Content Outline for BCPPS®
Refer to the Pediatric Pharmacy Examination Content Outline here for details on eligibility requirements, effective dates, and more.
The examination content outline is a product of a job analysis, also known as a role delineation study, that includes discussions with a panel of 15-20 subject matter experts who represent the specialty area. These experts determine the competencies required for safe and effective pharmacy practice in the specialty area and engage board-certified pharmacists through a validation survey for their endorsement of the identified competencies. The job analysis process is conducted every 5 years to help ensure that the competencies in the examination content outline reflect current pharmacy practice in the specialty area.
Click here to review the BCPPS® Job Analysis Summary.
Important Resources
Logging CPD Activities (Video)
Watch a step-by-step video walkthrough of how to report CPD activities in MyBPS once a certificant begins a new certification cycle. For CPD categories and descriptions, see the “How will CPD activities contribute to recertification?” question in the CPD FAQs.
CPD Annual Reflection and Plan (ARP) Sample
Click here to view a sample Annual Reflection and Plan (ARP) to help guide formatting and structure for your CPD annual reflection and learning plan.
CPD Activity Evaluation Sample
Click here to view a sample CPD activity evaluation (scholarly activity) to help guide how evaluations may be documented for CPD credit. This sample is for guidance and is not the only acceptable format.
Frequently Asked Questions
After review of the BPS Recertification Guide and specialty certification page, some applicants may still have questions. Visit this page to see frequently asked questions from pharmacists pursuing board certification like you!
Sample Examination Items
Sample Items for BCPPS® Examinations
The sample examination items for BCPPS® examinations are made available by BPS for the purposes of familiarizing certification candidates and other stakeholders with the structure and format of BPS certification examinations. This is not meant for use as a self-assessment. Performance on any of these items does not correlate with performance on the actual examination.
The content of these examples is meant to be illustrative of actual examination items, but these items do not appear on the certification examination and are not meant to identify the scope of the examination. For a more comprehensive indication of the scope of the certification examination, please refer to the BCPPS® Exam Content Outline.
Examination items are in multiple-choice format. The great majority of examination items are multiple-choice with a single response from among four options. Some examinations may include a small percentage of items that require selection of multiple (three or four) responses from among a larger set of available (up to eight) options. Examinations items may also be supplemented by an image.
View the examination items down below.
Using the Mosteller equation, what is the estimated body surface area of a 6-year-old patient who is 122 cm tall and weighs 24 kg?
Correct!
Incorrect!
Correct!
Incorrect!
Correct!
Incorrect!
A patient with asthma in the emergency department is still in distress after receiving three treatments of albuterol/ipratropium and methylprednisolone 1 mg/kg. Which adjunctive therapy would be most appropriate?
Correct!
Incorrect!
| Na | 150 mEq/L |
| K | 4.1 mEq/L |
| Cl | 100 mEq/L |
| HCO3- | 4 mEq/L |
| BUN | 25 mg/dL |
| SCr | 1.2 mg/dL |
| Glucose | 459 mg/dL |
| Venous pH | 6.9 |
Which treatment should be initiated first to treat this child's underlying illness?
Correct!
Incorrect!
An 8-year-old child reports leg swelling and decreased urine output. Urinalysis is significant for 500 ng/dL protein and positive for nitrite. A renal biopsy shows focal segmental glomerulosclerosis. Which initial treatment is most appropriate for this child?
Correct!
Incorrect!
Which is the most appropriate first-line treatment for functional constipation in a 1-year-old child?
Correct!
Incorrect!
A 16-day-old full-term neonate presents to the emergency department with seizures. Sepsis and meningitis are suspected, and cultures are obtained. Which antibiotic regimen is most appropriate for this neonate?
Correct!
Incorrect!
Which alternative therapy has shown effectiveness in treating irritable bowel syndrome in pediatric patients?
Correct!
Incorrect!
Which category is described as "Error, Death" by the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP)?
Correct!
Incorrect!
Which is an accurate statement regarding permission for patient participation in a study?
Correct!
Incorrect!
A new diagnostic test to be used in children has been developed. The clinical testing reveals the following:
| True positive | 145 |
| False positive | 30 |
| True negative | 50 |
| False negative | 5 |
What is the positive predictive value for this test?
Correct!
Incorrect!
Share the quiz to show your results !
Subscribe to see your results
I got %%score%% of %%total%% right
Loading...
Testimonials

Being one of the first Board-Certified Pediatric Pharmacy Specialist has identified me as an expert in pediatric pharmacotherapy and the ‘go to’ person by health care providers and families. As a professor, board certification has allowed me to develop an advance practice level experience for future pharmacist.

BPS certification has transformed my career as a pharmacist. The recognition of my specialized knowledge brings immense professional satisfaction and validates my commitment to the highest standards of patient care. It fosters my professional growth by ensuring I’m staying current with evolving practices and opens doors for new opportunities.

I maintain my BCPPS and BCPS credentials to remain up-to-date in a variety of patient populations. Even after moving into academic administration, these credentials facilitate conversations within the pharmacy community around the importance of board certification.

Each patient population is unique and important, and so are our pharmacist skills to treat them. As a pediatric pharmacist, the ability to obtain multiple BPS certifications helps to reflect the diversity and needs of all the obstetric, pediatric, and critically ill patients I have proudly served in my practice.

To me, it was a clear choice to become certified in pediatric pharmacy since it reflected my specialty residency training and my current practice area. Passing this exam was a personal achievement for me and preparing for the exam was a great way to review topics and guidelines that I did not use in my day-to-day practice.
Certification Verification
BPS offers the ability to search and verify a Board-Certified Pharmacist by name or credential number.